%0 Journal Article
%T Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
%A Yoshinami T
%A Nozawa K
%A Yokoe T
%A Ozaki Y
%A Nishio H
%A Tsuchihashi K
%A Ichihara E
%A Miura Y
%A Endo M
%A Yano S
%A Maruyama D
%A Susumu N
%A Takekuma M
%A Motohashi T
%A Ito M
%A Baba E
%A Ochi N
%A Kubo T
%A Uchino K
%A Kimura T
%A Kamiyama Y
%A Nakao S
%A Tamura S
%A Nishimoto H
%A Kato Y
%A Sato A
%A Takano T
%J Int J Clin Oncol
%V 29
%N 6
%D 2024 Jun 23
%M 38649648
%F 3.85
%R 10.1007/s10147-024-02504-4
%X <B>BACKGROUND: </B>Granulocyte colony-stimulating factor (G-CSF) is widely used for the primary prophylaxis of febrile neutropenia (FN). Two types of G-CSF are available in Japan, namely G-CSF chemically bound to polyethylene glycol (PEG G-CSF), which provides long-lasting effects with a single dose, and non-polyethylene glycol-bound G-CSF (non-PEG G-CSF), which must be sequentially administrated for several days.<BR><B>METHODS: </B>This current study investigated the utility of these treatments for the primary prophylaxis of FN through a systematic review of the literature. A detailed literature search for related studies was performed using PubMed, Ichushi-Web, and the Cochrane Library. Data were independently extracted and assessed by two reviewers. A qualitative analysis or meta-analysis was conducted to evaluate six outcomes.<BR><B>RESULTS: </B>Through the first and second screenings, 23 and 18 articles were extracted for qualitative synthesis and meta-analysis, respectively. The incidence of FN was significantly lower in the PEG G-CSF group than in the non-PEG G-CSF group with a strong quality/certainty of evidence. The differences in other outcomes, such as overall survival, infection-related mortality, the duration of neutropenia (less than 500/μL), quality of life, and pain, were not apparent.<BR><B>CONCLUSIONS: </B>A single dose of PEG G-CSF is strongly recommended over multiple-dose non-PEG G-CSF therapy for the primary prophylaxis of FN.